Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 11;34(9):161.
doi: 10.1007/s12032-017-1022-2.

Bcl-2 antigen expression in luminal A and triple-negative breast cancer

Carla Solange Escórcio-Dourado  1 , Luana Mota Martins  1 , Camila Maria Simplício-Revoredo  1 , Fabiane Araújo Sampaio  1 , Cléciton Braga Tavares  1 , João Paulo da Silva-Sampaio  2 , Umbelina Soares Borges  2 , Francisco Adelton Alves-Ribeiro  1 , Pedro Vitor Lopes-Costa  2   3 , José Charles Lima-Dourado  1 , Benedito Borges da Silva  4   5   6   7
Affiliations

Bcl-2 antigen expression in luminal A and triple-negative breast cancer

Carla Solange Escórcio-Dourado et al. Med Oncol. .

Abstract

Biomarkers for the prognosis of breast cancer have been routinely used in clinical practice, including the expression of hormone receptors, Ki-67 and HER-2. More recently, Bcl-2 has been recognized as an important prognostic factor in breast cancer, although controversies persist with respect to the significance of its expression. The aim of the present study was to evaluate Bcl-2 antigen expression in luminal A and triple-negative breast cancer. Sixty women with invasive ductal carcinoma were included in the study and divided into two groups: Group A (luminal A) and Group B (triple-negative), with 30 cases in each group. Immunohistochemistry was performed on tissue sections to evaluate Bcl-2 antigen expression. Fisher's exact test was used to compare the proportions of cases with cells expressing Bcl-2 between the two subtype cancer groups, with statistical significance being established at p < 0.05. The number of cases with cells expressing Bcl-2 in Groups A and B was 26 (86.7%) and 12 (40.0%), respectively (p < 0.0003). In the present study, the expression of the anti-apoptotic protein Bcl-2 was greater in luminal A breast cancer tissue samples compared to triple-negative breast cancer.

Keywords: Apoptosis; Bcl-2; Breast cancer; Prognosis; Tumor aggressiveness.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1047-54 - PubMed
    1. J Clin Oncol. 2013 Jan 10;31(2):203-9 - PubMed
    1. Endocr Relat Cancer. 1999 Mar;6(1):25-8 - PubMed
    1. Rom J Morphol Embryol. 2012;53(1):155-60 - PubMed
    1. Cancer. 1998 Apr 1;82(7):1296-302 - PubMed

MeSH terms

LinkOut - more resources